EdiGene is dedicated to the development of genome editing technology for human health. Genome editing technology enables the targeted modification of genetic information in human cells, including gene knockout, knock-in, and targeted mutations. They aim at providing high-quality products and services for the patients, the pharmaceutical industry, and the scientific research community with the most advanced genome editing technology.EdiGene innovates and applies genome editing technology to developing human therapeutic products. Their therapeutic approach is to treat diseases at the molecular level, making gene therapy safer and more effective.
Our mission is to translate the cutting-edge genome editing technologies into novel therapeutics for genetic diseases and cancer, and into creative solutions to advance drug discovery. We leverage our proprietary platforms to develop genome-editing therapies for a wide range of diseases, and to conduct high-throughput genome screening to enable dissection of functional big data in biological contexts.
Total Funding: $118 M
Funding Stage: Series B
Business Stage: Scaling Up
Market: B2B
Company Size: 51 to 100
Founded: 2015
Production Engineer
Guangzhou, Guangzhou
Medical Director/Senior Medical Director
Beijing, Haidian
Production Process Director/Associate Director
Guangzhou, Guangzhou
Clinical Auditor (CRA)
Beijing, Haidian
Analytical R&D Scientist
Beijing, Haidian
